The global insulin pump market size was valued at USD 4.1 billion in 2022 and is anticipated to grow at a compound annual growth rate (CAGR) of 9.8% from 2023 to 2030. The factors influencing market growth include technological advancements and the rising adoption of insulin pumps over traditional methods. Insulin pumps are quite practical for those who need several insulin injections each day. Because they are less intrusive, these devices are widely used by the patient population. The market's expansion is mostly attributable to the expanding elderly population, rising diabetes incidence, and rising obesity prevalence. To improve compliance and interaction with IT devices further, businesses are creating next-generation insulin pumps with cutting-edge technology, boosting the market's expansion. Technology advancements such as home infusion treatment and artificial pancreas are also projected to generate considerable growth prospects in the near future. Additionally, as the use of insulin pumps becomes more well-known, markets in developed and developing nations are expanding.
An increase in the incidence of diabetes due to aging, obesity, and an unhealthy lifestyle is one of the factors contributing to the growth of the market. Obesity is a major factor causing diabetes, leading to increased incidences of diabetes-associated ophthalmic disorders. Risk factors, such as obesity, smoking, and high cholesterol, are expected to boost the prevalence of type II diabetes.
Diabetes is increasing globally and is one of the leading causes of death, with an increased chance of acquiring various other health issues. The number of people diagnosed with type 1 diabetes is also rising, boosting market growth. Furthermore, the market is driven as people have become more aware of the disease of the growing senior population and increasingly sedentary lifestyles.
According to the IDF (International Diabetes Foundation) Atlas, diabetes will be responsible for around 6.7 million fatalities in 2021, and the overall number of diabetic patients is predicted to increase by 51% by 2045.
Increasing government initiatives for global awareness about Medicare policies and the management of diabetes are also fuelling market growth. Furthermore, there has been a rise in healthcare spending and an increase in the demand for improved tubeless insulin pumps that are both discreet and user-pleasant. This is expected to drive market growth during the forecast period.
When the pancreas is unable to produce enough insulin, diabetes develops when the body's glucose levels fall. Alcohol and cigarette use are two rapidly changing lifestyle choices contributing to a rise in diabetes cases worldwide. The increased incidence of diabetes is also largely attributed to the rising prevalence of obesity worldwide. The need for numerous insulin injections and continuous blood glucose monitoring due to type 1 diabetes (T1D) expands the market for pumps, alternative insulin delivery systems, and glucose monitors.
An insulin pump makes it possible to manually or automatically administer insulin. When necessary, such as before a meal, these pumps may give a larger set of insulin doses and a particular set of insulin doses. Patients can connect these devices to their smartphones to calibrate blood glucose readings. People with diabetes face many daily challenges, such as knowing what to eat, understanding medical advice, and the impact of food and activity on sugar.
With the increase in awareness regarding diabetes management and care, electronic insulin pumps are being favored by both doctors and consumers. This can be attributed to the fact that new-generation pumps are convenient, safe, and provide accurate results compared to traditional methods. The anytime-anywhere nature of digital technology enables patients to address their health issues by connecting with the healthcare team and sharing data. The aforementioned factors are expected to propel the growth of the market. Furthermore, the increasing number of initiatives undertaken by governments and nonprofit organizations to increase awareness about diabetes is expected to boost the adoption of insulin pumps used for the treatment.
The market is segmented into patch and tethered pumps based on the types. The tethered pumps segment dominated the market and accounted for the largest revenue share of 78% in 2022. This segment is expected to witness a CAGR of 9.8% during the forecast period. Tethered pumps have flexible tubing between the pump and the cannula. The large market size of the segment is majorly attributed to the reliability of these traditional pumps and the number of products available in the market.
The patch pump segment is expected to witness a robust CAGR of around 10.9% during the forecast period. Patch pumps are small and can be directly attached to the skin's surface. The market's high growth rate is mainly attributed to its benefits, such as no tubing in patch pumps and its remote control, which may also serve as a blood glucose meter. Moreover, pumps are integrated with calculators that help determine the exact insulin dosage required by patients. This helps reduce the over dosage of insulin and its associated effects. These factors are likely to boost the market's growth during the forecast period.
Medtronic’s MiniMed insulin pumps segment dominated the market and captured the largest revenue share of around 50.2% in 2022, owing to the high adoption rate and technological advancement. The growth of the MiniMed product line is primarily driven by a strong foothold and regional presence of Medtronic and the launch of its MiniMed 670G system, the world’s first hybrid closed-loop system.
The My Life Omnipod/ ypsomed pump segment is expected to exhibit the highest CAGR of 19.6% during the forecast period. Due to the absence of tubing, the omnipod system is preferred by many since it allows for greater exercise flexibility. Additionally, one does not need to stop taking insulin when showering or swimming.
The insulin set insertion devices segment dominated the market and accounted for the largest revenue share of 41.3% in 2022. The highest market share of this segment is majorly attributed to its use, such as in general infusion sets of insulin pumps being changed every two to three days and the high cost of infusion sets.
The insulin reservoir or cartridges segment is expected to witness a substantial growth rate of CAGR of 10% during the forecast period. The increasing adoption of tethered pumps drives the growth of the segment. This typically involves loading a cartridge of insulin into the reservoir or drawing insulin from a vial into the reservoir. These reservoirs can hold up to 300 units of insulin and do not require a change for at least 2-3 days. The aforementioned factors are expected to drive the growth of the segment.
The hospitals and clinics segment dominated the market and accounted for the largest revenue share of 44.6% in 2022. The large share of the segment is attributed to the availability of skilled healthcare professionals, increasing government funding, and rising private sector investment in the healthcare sector.
The homecare segment is expected to witness the fastest CAGR of 10.2% during the forecast period. The sector's growth is attributed to the increasing awareness about insulin pump use and the high adoption of these products at home due to their ease of use. Moreover, increasing usage of patch pumps, which are small and easy to carry, is also expected to propel the market during the forecast period.
North America dominated the insulin pump market and captured the largest revenue share of around 45.8% in 2022, owing to major players in insulin pumps. Furthermore, the increasing prevalence of obesity, high treatment costs, technological advancement, and product launches are also expected to drive the market in the region. Europe is also expected to capture a significant market share over the forecast period due to an increase in the geriatric population, which is prone to diabetes. Moreover, improvements in its healthcare sector and the implementation of advanced medical products are augmenting the demand for insulin pumps in the region.
Asia Pacific is projected to be a lucrative region for the insulin pumps market. Increasing healthcare funding and government initiatives to spread awareness about diabetes are major factors aiding growth in this region. China is expected to lead the Asia Pacific region in 2022 owing to its economic growth and large diabetes population. Furthermore, adopting new technology in developing economies is also anticipated to boost the market.
Key players are involved in adopting strategies such as mergers and acquisitions, partnerships, and the launch of new technologically advanced products and services to strengthen their foothold in the market. Key players are significantly investing in research and development to manufacture technologically advanced products. For instance, in June 2019, Medtronic announced its partnership with Tidepool to create an interoperable automated insulin pump system. The former plans to launch a new Bluetooth-enabled MiniMed insulin pump, which will be compatible with Tidepool Loop, a hybrid. On June 2, 2022, Insulet Corporation, a world leader in tubeless insulin pump devices and technology, announced an investment of approximately USD 200 million in its upcoming manufacturing facility in Johor over the next five years. This would produce the company’s Omnipod Insulin Management System as part of its ambition to strengthen its worldwide manufacturing capabilities
In April 2022, Ypsomed announced a collaboration with Abbott and CamDiab to develop an integrated AID (automated insulin delivery) system. The new integrated AID system is being designed to link Abbott's FreeStyle Libre 3 with Ypsomed's MyLife YpsoPump to make a smart, and automatic procedure for delivering insulin with realistic glucose data
On 3 June 2022, Diabeloop, a world leader in therapeutic AI, and SOOIL Development Company, a leader in superior diabetes therapy announced an agreement for worldwide development at the American Diabetes Association Scientific Sessions. The collaboration is anticipated to establish clinical trials for expanding their cooperation and provide access to their goods to as many patients as possible through new innovative products.
Report Attribute |
Details |
Market size value in 2023 |
USD 4.4 billion |
Revenue forecast in 2030 |
USD 8.6 billion |
Growth rate |
CAGR of 9.8% from 2023 to 2030 |
Base year for estimation |
2022 |
Historical data |
2018 - 2021 |
Forecast period |
2023 - 2030 |
Report updated |
December 2023 |
Quantitative units |
Revenue in USD million and CAGR from 2023 to 2030 |
Report coverage |
Revenue forecast, company ranking, competitive landscape, growth factors, and trends |
Segments covered |
Type, product, accessories, end-use, region |
Regional scope |
North America; Europe; Asia Pacific; Latin America; MEA |
Country scope |
U.S.; Canada; UK; Germany; France; Italy; Spain; Denmark; Sweden; Norway; China; Japan; India; Australia; South Korea; Thailand; Brazil; Mexico; Argentina; Saudi Arabia; South Africa; UAE; Kuwait |
Key companies profiled |
Medtronic plc; Hoffmann-La Roche Ltd; Tandem Diabetic Care, Inc.; Insulet Corporation; Ypsomed; Cellenovo; Sooil Development; Valeritas, Inc; JingasuDelfu Co., Ltd.
|
Customization scope |
Free report customization (equivalent up to 8 analyst’s working days) with purchase. Addition or alteration to country, regional & segment scope |
Pricing and purchase options |
Avail customized purchase options to meet your exact research needs. Explore purchase options |
This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2030. For this study, Grand View Research has segmented the global Insulin pump marketbased on type, material, application, and region:
Type Outlook (Revenue, USD Million, 2018 - 2030)
Patch pumps
Tethered pumps
Product Outlook (Revenue, USD Million, 2018 - 2030)
MiniMed (630G, 670G, and VEO)
Accu-Chek (Combo, Insight, and Solo)
Tandem (T: slim X2, G4, T: flex Delivery System)
Omnipod
My life omnipod
Others
Accessories Outlook (Revenue, USD Million, 2018 - 2030)
Insulin reservoir or cartridges
Insulin set insertion devices
Battery
End-use Outlook (Revenue, USD Million, 2018 - 2030)
Hospitals & clinics
Homecare
Laboratories
Regional Outlook (Revenue, USD Million, 2018 - 2030)
North America
U.S.
Canada
Europe
UK
Germany
France
Italy
Spain
Sweden
Norway
Denmark
Asia Pacific
China
Japan
India
Australia
Thailand
South Korea
Latin America
Brazil
Mexico
Argentina
Middle East and Africa
Saudi Arabia
South Africa
UAE
Kuwait
b. The global insulin pump market size was estimated at USD 4.1 billion in 2022 and is expected to reach USD 4.4 billion in 2023.
b. The global insulin pump market is expected to grow at a compound annual growth rate of 8.6% from 2023 to 2030 to reach USD 8.6 billion by 2030.
b. North America dominated the insulin pump market with a share of 45.8% in 2022. This is attributable to the increasing prevalence of obesity, treatment cost, rising patient awareness about early disease diagnosis and treatment, supportive reimbursement policies, and the increasing prevalence of diabetes.
b. Some key players operating in the insulin pump market include Medtronic plc, Hoffmann-La Roche Ltd, Tandem Diabetic Care, Inc., Insulet Corporation, Ypsomed, Cellenovo, Sooil Development, Valeritas, Inc., and Jingasu Delfu Co., Ltd.
b. Key factors that are driving the insulin pump market growth include rising technological advancement and adoption of insulin pumps over traditional methods.
NEED A CUSTOM REPORT?
We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities. Contact us now
We are GDPR and CCPA compliant! Your transaction & personal information is safe and secure. For more details, please read our privacy policy.
"The quality of research they have done for us has been excellent."